| Imagery Source: Wikimedia Commons/Coolcaesar |
| Information Source: Merck & Co |
- Total Worldwide Sales Were $15.5 Billion, a Decrease of 2% From First Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 1%
|
-
- KEYTRUDA Sales Grew 4% to $7.2 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 6%
|
-
- WINREVAIR Sales Were $280 Million
|
-
- Animal Health Sales Grew 5% to $1.6 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 10%
|
-
- GARDASIL/GARDASIL 9 Sales Declined 41% to $1.3 Billion; Excluding the Impact of Foreign Exchange, Sales Declined 40%
|
- GAAP EPS was $2.01; Non-GAAP EPS was $2.22
|
- Presented Compelling Data From a Diverse Range of Programs, Including:
|
-
- Phase 3 Trial of Subcutaneous Pembrolizumab With Berahyaluronidase Alfa
|
-
- Phase 3 ZENITH Trial of WINREVAIR for the Treatment of Adults With PAH (WHO Group 1) Functional Class III or IV at High Risk of Mortality
|
-
- Phase 3 Trials Evaluating Investigational, Once-Daily, Oral Two-Drug Regimen of Doravirine/Islatravir for the Treatment of Adults With Virologically Suppressed HIV-1 Infection
|
- Expanded Pipeline Through Exclusive License Agreement With Hengrui Pharma for an Investigational Oral Small Molecule Lp(a) Inhibitor; Transaction Expected to Close in Second Quarter 2025
|
- Full-Year 2025 Financial Outlook
|
-
- Continues To Expect Worldwide Sales To Be Between $64.1 billion and $65.6 billion
|
-
- Now Expects Non-GAAP EPS To Be Between $8.82 and $8.97; Outlook Revised to Reflect Negative Impact From Anticipated One-Time Charge of Approximately $0.06 per Share Related to License Agreement With Hengrui Pharma.
|
-
- Outlook Absorbs an Estimated $200 Million of Additional Costs for Tariffs Implemented to Date.
|
| Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025. |
| “Our company made strong progress to start the year, with increasing contributions from our newer commercialised medicines and vaccines and continued advancement of our pipeline,” said Robert M. Davis, chairman and chief executive officer, Merck. “We are working with focus and urgency to both realise the full potential of our near-term opportunities and to rapidly progress the next wave of innovation that will positively impact the lives of patients and drive future value creation for all of our stakeholders.” |
| For the first quarter of 2025, Generally Accepted Accounting Principles (GAAP) earnings per share (EPS) assuming dilution were $2.01, and non-GAAP EPS were $2.22. GAAP and non-GAAP EPS in the first quarter of 2024 include a charge of $0.26 per share for the acquisition of Harpoon Therapeutics, Inc. (Harpoon). |
| Non-GAAP EPS excludes acquisition- and divestiture-related costs, costs related to restructuring programs, and income and losses from investments in equity securities. |
| For the full document, click the link below |
| Merck & Co. Inc |
| Stay ahead of the curve! Subscribe to InsidEntity for daily updates on all your favourite companies. |
